SCHEMBL21708017

SCHEMBL21708017

Cc1ccc2nc(-c3cccc(Cl)c3)cn2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 13/20 0.65
RAB9A P51151 12/20 0.65
ALDH1A1 P00352 9/20 0.65
KDM4E B2RXH2 9/20 0.65
SMN1; SMN2 Q16637 6/20 0.65
HPGD P15428 6/20 0.65
PKM P14618 5/20 0.65
KMT2A Q03164 3/20 0.65
TP53 P04637 3/20 0.65
HSD17B10 Q99714 3/20 0.65
TSHR P16473 2/20 0.65
CDK5 Q00535 1/20 0.65
CDK5R1 Q15078 1/20 0.65
MEN1 O00255 2/20 0.61
PAX8 Q06710 2/20 0.61
MITF O75030 1/20 0.61
KDM5A P29375 1/20 0.61
KDM5C P41229 1/20 0.61
GFER P55789 2/20 0.59
POLB P06746 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2127099 0.84 NPC1 (0.66) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL21708003 0.82 NPC1 (0.65) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL21708004 0.82 NPC1 (0.65) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL1691254 0.81 NPC1 (0.80) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL1987470 0.80 NPC1 (0.96) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL2127573 0.80 ALDH1A3 (0.58) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL6391701 0.80 RAB9A (0.69) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL1691197 0.79 ALDH1A3 (0.70) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL8102158 0.79 NR1H4 (0.50) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2
SCHEMBL2128768 0.78 RAB9A (0.75) NPC1RAB9AALDH1A1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US claimed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP claimed
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US disclosed
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US disclosed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP disclosed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine DOT1L, NSD1, KDM3A NPC1 4209/4885RAB9A 3350/4885ALDH1A1 187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.